Traders Network Show Archives - 1-800-PublicRelations "1800pr"

11 Jan

1800PR Produces First ‘United Nations Movie Premiere’ with Arnold Schwarzenegger “Wonders of the Sea 3D”

Public Relations firm “1800pr” aligns Arnold Schwarzenegger & Jean-Michel Cousteau’s “Wonders of the Sea 3D” movie with UN SDG 14 through a social impact event

1800PR is proud to announce the PR agency has successfully completed the first movie premiere at the United Nations with Arnold Schwarzenegger’s & Jean-Michel Cousteau’s “Wonders of the Sea 3D” Movie. The event which was the first of its kind at the United Nations Headquarters in New York, NY, aligned the goals of the film and the pubic messaging and goals of United Nations in support of UN SDG 14 “Life Under Water”. Through a strategic public-private partnership collaboration, 1800pr and its partners, in collaboration with the office of UN for partnerships, positioned the “Wonders of the Sea 3D” movie and its message as an amplifier a social impact initiative to help inspire social change.

WATCH MOVIE TRALER: https://www.youtube.com/watch?v=FWtQqyg0TTc

Daniel Thomas, Director of Communications & Spokesperson for the President of the UN General Assembly, Matt Bird CEO of 1800PR and sports and entertainment TV personality Pat O’Brien co-hosted the event with guests; Co-Star Fabian Cousteau (son of Jean-Michel Cousteau), Co-Director Jean-Jacque Mantello and his brother and Producer, François Mantello, who also took to the podium and addressed the crowd.

in cooperation with [John Paul DeJoria portfolio of companies] that helped make the event possible.

Quote: Daniel Thomas, Chief Communications Officer UN Global commented; “It was an incredible event and the first of its kind at the United Nations.”

Quote: Wonder of the Sea 3D Director Jean-Jacque Mantello and Producer Francois Mantello commented, “We would like to thank 1800pr who organized and produced this event and allowing us to present our film “Wonders of the Sea 3D” at the United Nations. We know how difficult it is to organize an event inside this prestigious institution, and especially, a 3D projection which had never been done before. The theatre was packed and we had amazing feedback from the hundreds of guests who attended.”

Quote: Pat O’Brien, Co-Host of the event and TV personality said, “In all my 35+ years in network television with NBC and CBS, I’ve worked with many PR agencies. 1800pr stands out – not only are they thorough, but they think differently, act differently and find ways to align brands with meaningful social impact initiatives with a purpose, and just get it done. What a team!”

Our Impact Pledge: In 2015 1800pr made a pledge to support the UN SDGs with media, communications and strategic advisory services to help better-the-world through strategic public-private partnerships programs by becoming and advocate and evangelist for the SDG goals and its message of social change. To date, 1800pr has reached more than one (1) billion people* by supporting the UN SDG initiatives with our news and content distributions services, media relations work and strategic social impact events and media coverage. *Source: Data and reporting provided by Meltwater and ComScore.

CONTACTS

Partnerships:
Matt Bird
CEO
1800pr
(646) 401-4499
matt.bird@1800pr.com

Matt Bird LinkedIn

By Matt Bird, President 1800PR News, Content Marketing, Digital PR, Event, PR Agency Representation, PR Strategy, Traders Network Show, Uncategorized Arnold Schwarzenegger, Daniel Thomas, event, Jean-Michel Cousteau, John Paul DeJoria, matt bird, PR Agency, UN SDGs, United Nations Comments Off Read more...

FINRA Investor Education Foundation Releases Latest National Financial Capability Study (NFCS) While Americans as a whole are feeling less financial stress, making ends meet remains a daily struggle for women, millennials, African-Americans, Hispanics and those without a high school education, according to the NFCS, one of the largest and most comprehensive financial capability studies in the United States. The study measures four key components of financial capability—making ends meet, planning ahead, managing financial products and financial knowledge and decision making. The event will be co-hosted with the Global Financial Literacy Excellence Center (GFLEC).

03 Aug

Media Advisory: FINRA Foundation Releases latest National Financial Capability Study (NFCS)

FINRA Investor Education Foundation Releases Latest National Financial Capability Study (NFCS)
While Americans as a whole are feeling less financial stress, making ends me

et remains a daily struggle for women, millennials, African-Americans, Hispanics and those without a high school

education, according to the NFCS, one of the largest and most comprehensive financial capability studies in the United States. The study measures four key components of financial capability—making ends meet, planning ahead, managi

ng financial products and financial knowledge and decision making. The event will be co-hosted with the Global Financial Literacy Excellence Center (GFLEC).

By Matt Bird, President Blog, Crisis Communications, Traders Network Show, Uncategorized 1800PR, finra, National Financial Capability Study, NFCS Comments Off Read more...

16 Feb

CEO Kevin Lasser of JEMS Technology to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 7th 2015 Hosted by Michael Yorba, 2:30pm ET/11:30am PT/1:30pm CT

ORION, MI – (Mar 6, 2015) – JEMS Technology, a telehealth solutions company that improves security, immediacy, quality, and mobility, announced today that Chief Executive Officer (CEO) Kevin Lasser will be featured live on Saturday, March 7, 2015 at 2:30pm ET by host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network Show.” In this exclusive interview, Kevin Lasser will discuss how Healthcare providers have suffered without a reliable telemedicine system for secure real-time mobile until “The JEMS™ Mobile Health System.” The system is available everywhere, including over 3G, 4G, and “coffee shop” Wi-Fi. He will also discuss how JEMS Technology is now being utilized in non-healthcare markets.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide stream are below.

Date: March 7, 2015
Start Time: 2:30pm ET | 11:30am PT | 1:30pm CT
Network: Clear Channel / iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Trader’s Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Clear Channel
Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. For more information visit its website at www.clearchannel.com.

About The Trader’s Network Show
For the past six years “The Trader’s Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… Shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Trader’s Network Show.

About Kevin Lasser
Mr. Kevin Lasser has 29 years of experience in business building, finance, and technology solutions. Mr. Lasser is Chief Executive of JEMS Technology — the mobile health care solution that provides a consult anytime, anywhere. He oversees global business operations for JEMS — which is becoming the preferred telehealth choice for health care providers in North America, and Asia in both private and public institutions. Additionally, he is a committee member of the inaugural mobile health HIMSS (Healthcare Information and Management Systems Society) committee and past chair of MTAM’s (Mobile Technology Association of Michigan) mHealth Advisory Council.

Prior to JEMS, Mr. Lasser was Chief Executive Officer and co-founder of Encryption Security Solutions (ESS) and Pure Entropy Technologies (PET) where he led both companies in becoming best in class providers of encryption/cyber security solutions to private (through ESS) and public (through PET) institutions.

Prior to ESS and PET, Mr. Lasser was President and founder of Sage Financial Corporation (Sage). Sage was consistently honored with “Top Ten Money Finders Group Awards” from esteemed financial organizations such as GE Capital, Pitney Bowes Financial and Maryland National Financial Corp. Sage funded approximately $220 million for small to mid-size businesses over a ten year period.

Mr. Lasser is a well sought after key thought leader on matters of telehealth. He has spoken on many topics including “The ROI in Health Care on Mobile Devices,” “Bio Medical Wireless Technologies,” “Health Care Technology for Critical Access Facilities,” “The Impact of Mobile Devices in Healthcare,” and the recipient of numerous professional awards.

About JEMS Technology
Headquartered in Orion, Mich., JEMS Technology’s focus is simple: Consult. Anytime. Anywhere. It specializes in secure, encrypted (HIPAA compliant) real-time video to hand held devices, including the iPhone, iPad, Android-based phones and Android-based tablets. JEMS Technology is focused on the healthcare market, where remote access to secure live video can assist healthcare providers to deliver better care. From real-time video to phone connectivity, JEMS Technology is effective, easy-to-use and easy to implement.

The JEMS platform is adaptable and scalable — the JEMS suite of solutions is being utilized in various health care disciplines (tele-neurology, tele-ALS, tele-OR, tele-OB, tele-cardiology, etc). in both private and public institutions (DHS, VA, Department of Justice). JEMS is also delivering immediate best in class health care for better outcomes from places other than health care facilities (first responder vehicles, residences, etc).

Additionally, JEMS is now being utilized in non-healthcare markets. One such example is “tele-engineering.” Rather than travel to various manufacturing plants to repair equipment, an engineer can advise others on how to make those repairs in an immediate, efficient and secure manner from the convenience of their smart device.

For more information on JEMS Technology, visit http://www.JEMSTech.com.

A 1800PublicRelations.com PR Event…

Contact
Interview Press / Media Contact
Matthew Bird
President
1-800-PublicRelations, Inc.
917.409.8211
matt.bird@1800pr.com
www.1800pr.com

By support Traders Network Show Comments Off Read more...

16 Feb

WindStream Technologies, Inc. CEO Daniel Bates to Be Interviewed on Clear Channel – iHeart Business Talk Radio’s “The Trader’s Network” on December 5, 2014

Live Interview Airs on The Trader’s Network Radio Show, Hosted by Michael Yorba, 9:30pm ET/6:30pm PT/8:30pm CT

NORTH VERNON, IN — 12/05/14 — WindStream Technologies, Inc. (OTCBB: WSTI), the Company that has developed and tested the first-of-its-kind, integrated, hybrid energy solution and is now marketing and selling SolarMills^® to a worldwide customer base, announced today that CEO Daniel Bates will be interviewed live by host Michael Yorba on Clear Channel – iHeart Business Talk Radio’s The Traders Network Show. In this exclusive 2-segment interview, Mr. Bates will discuss how the company is engaged in the development and commercialization of wind driven electrical generation products in the United States and internationally. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: December 5, 2014
Start Time: 9:30pm ET | 6:30pm PT | 8:30pm CT (U.S.)
Network: Clear Channel – iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About WindStream Technologies, Inc.: WindStream Technologies, Inc. was established in 2008 with the goal of designing, prototyping and manufacturing affordable and scalable renewable energy technologies for a global marketplace. The Company has developed and tested the first-of-its-kind, integrated, hybrid energy solution and is now marketing and selling SolarMills^® to a worldwide customer base.

In 2009, the Company set up its Research and Development facilities at the Purdue Research Center in New Albany, Indiana with an academic alliance with Purdue University and a generous grant from the State of Indiana. Engineers were hired for their expertise in fluid dynamics, turbine design, power electronics and electro mechanical engineering. The Company set out to build a system that was unique in the industry focusing on a highly efficient design that was able to leverage manufacturing techniques commonly found in mass-production environments.

Upon completing many rounds of prototyping and testing, both in the lab and in real world environments, WindStream set up its manufacturing facilities in 2011 in a 50,000 sq. ft. facility in North Vernon, Indiana where it currently manufactures and ships its products to customers all over the world.

The Company has recently set up its India/South Asia Operations under the name of WindStream Energy Technologies, Private Limited with the intent of servicing that part of the world with products manufactured in India under the close inspection of WindStream USA. WindStream will continue to manufacture and ship its products globally from its Indiana facilities.

The Company has been granted U.S. patents for its technology with a suite of additional patents both domestic and international in various stages of prosecution.

About Clear Channel: Clear Channel’s Media and Entertainment division has the largest reach of any radio or television outlet in America with 243 million monthly listeners. It serves 150 cities through 850 owned radio stations in the U.S., as well as more than 140 stations in New Zealand and Australia. www.clearchannel.com.

About The Traders Network Show: For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 6am – 7:30am and 2pm – 3pm CT, Monday-Friday. Host Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show. To inquire about being a guest on this show please contact “1800pr” at www.1800PublicRelations.com.

Company Contact:
WindStream Technologies, Inc.
819 Buckeye Street
North Vernon, IN 47265
+1 (812) 953-1481
http://www.windstream-inc.com

Interview Press / Media Contact:
Matthew Bird
President
1-800-PublicRelations
917.409.8211
Matt.Bird@1800pr.com
www.1800pr.com

By support Traders Network Show Comments Off Read more...

16 Feb

President & CEO Leen Kawas, PhD of M3 Biotechnology, Inc. to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 14th 2015 hosted by Michael Yorba, 1:30pm ET/10:30am PT/12:30pm CT

SEATTLE, WA–(Mar 13, 2015) – Leen Kawas, Ph.D, CEO of an innovative young therapeutics company named M3 Biotechnology, Inc., that has a novel platform of drugs which could reverse the course of neurodegenerative diseases like Parkinson’s Disease and Alzheimer’s by inducing brain cells to grow again, will be interviewed on a Clear Channel iHeart Business Radio’s live worldwide stream.

Kawas will be interviewed live on Saturday, March 14, 2015, at 1:30 p.m. ET by host Michael Yorba on “The Trader’s Network,” to discuss M3’s growth-factor-modifying pharmaceuticals platform that has begun to attract significant interest having completed animal trials and now moving toward human trials.

We encourage all shareholders, analysts, industry professionals and interested parties to tune in live. The details and link to iHeart Radio’s live worldwide steam are below.

Date: March 14, 2015
Start Time: 1:30pm ET | 10:30am PT | 12:30pm CT
Network: Clear Channel/ iHeart Radio
Station: DFW 1190AM KFXR
KFXR Show: The Traders Network Show
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

About President and CEO Leen Kawas, PhD.
The young firm where Kawas became CEO on late 2013 has developed a drug, now moving toward initial human trials, a drug that would not merely slow but actually reverse the course of neurodegenerative diseases like Parkinson’s Disease and Alzheimer’s. Dr. Kawas was co-inventor of the drug and co-founder of M3.

In addition to co-inventing the drug MM-201 and guiding the company toward its funding goals, M3’s scientist has successfully obtained grant-funding from noteworthy national organizations like the National Institutes of Health, the Alzheimer’s Drug Discovery Fund and the Michael J. Fox Foundation and impressive grant support from the Life Science Discovery Fund in Washington State.

M3’s drug is not merely a novel technology to addressing the neurodegenerative diseases but the approach for which she plans to seek FDA approval is also novel, taking advantage of a fast-track designation the FDA has approved to dramatically reduce the time and data required to enhance efficiency in getting drugs to market.

Kawas unique combination of scientific and medical knowledge, starting her career as a clinical pharmacist and then getting her PhD in molecular Pharmacology, give her the credibility to lead the company in its next research-intensive phase. While growing the company’s science and licensing the technology out of Washington State University, Kawas was also able to raise more than $2 million from both dilutive and non-dilutive sources, including grants from the National Institute of Health (NIH), Alzheimer’s Drug Discovery and Michael J Fox Foundations, to support development of the therapeutics being advanced in M3, especially MM-201. Dr. Kawas’ goal and passion is entrepreneurship that leads to disease modifying pharmaceuticals that address critical unmet medical needs. And as a female entrepreneur with a scientific background, Kawas is committed to mentoring women in science and business and has been selected for programs to inspire women to go into those fields, and was featured as a role model for women in a profile recently in a Spokane, WA business magazine. For Kawas, the challenge of raising investment capital for her start-up company while overcoming the array of obstacles facing a 29-year-old Middle Eastern female are more than offset by the successes she has been able to achieve.

About M3 Biotechnology, Inc.
M3 is preparing for a Phase I clinical trial of its patented small molecule therapy, MM-201. MM-201 is an orally delivered drug that causes stem cells to differentiate into neuron cells at a rate faster than degenerative brain diseases, such as Parkinson’s and Alzheimer’s, destroys them. During this trial, it is expected that M3 will enter into a license agreement with one of six large pharmaceutical companies to complete the FDA approval process and prepare for commercially manufacturing and marketing the drug. As a disease modifying and feasibly delivered drug, it is expected that MM201 will become the standard of care for patients afflicted with these diseases.

MM-201, with its first-in-class growth actor-activation process and unique small-molecule characteristic, which represents an important opportunity for potential investors as M3 raises the funds necessary to enable MM-201 to move through human trials and to market. The uniqueness of MM-201 is that it is orally available, able to permeate the protective blood brain barrier and thus modify the effects of Parkinson’s disease (PD) and Alzheimer’s disease (AD).

M3’s initial development work has been supported by grants from both the Michael J. Fox Foundation and the Alzheimer’s Drug Discovery Foundation, Life Science Discovery fund financial support stemming from the understanding of those foundations of the novel paradigm that M3’s technology represents. This support shows the understanding that M3’s technology could, for the first time in a non-invasive way as compared to Deep Brain Stimulation and other technologies in the pipeline, stop and possibly reverse the clinical course of these diseases. In addition to the life-altering potential of this drug, success would quickly lead to domination in a multi-billion dollar market.

The drug has demonstrated efficacy in numerous animal models of neurodegenerative disease (NDD) including the rat scopolamine dementia model, the aged rat dementia model and the Rat 6-OHDA model of PD.

A 1800PublicRelations.com PR Event…

CONTACT INFORMATION

Interview Press / Media Contact:
Matthew Bird
President
1-800-PublicRelations, Inc.
917.409.8211
matt.bird@1800pr.com
www.1800pr.com

By support Traders Network Show Comments Off Read more...

16 Feb

CEO Tom Brophy of CUR Media, Inc. to Be Interviewed Live on Clear Channel’s “The Trader’s Network Show”

Live Interview to Air March 7th 2015 Hosted by Michael Yorba, 1:00pm ET/10:00am PT/12:00pm CT

GLASTONBURY, CT–(Mar 6, 2015) – CÜR Media, Inc. (OTCQB: CURM) (OTCBB: CURM) announced today that Founder and Chief Executive Officer (CEO) Tom Brophy will be interviewed live tomorrow by host Michael Yorba on Clear Channel — iHeart Business Talk Radio’s, “The Trader’s Network Show.”

In this exclusive double-segment interview, Mr. Brophy will discuss how CÜR Media is developing a next generation social music experience through the planned launch of CÜR Music, a social streaming music application and website that is being designed to enable its users to go beyond the limitations of traditional music streaming services. He will also discuss recent business developments that will shape the planned launch of CÜR Music later this year in the multi-billion dollar music industry.

All Shareholders, analysts, industry professionals and all interested parties are encouraged to listen live via Clear Channel’s iHeart Radio stream.

Date: March 7, 2015
Start Time: 1:00pm ET | 10:00am PT | 12:00pm CT (U.S.)
Network: Clear Channel — iHeart
Station: DFW 1190AM
KFXR Show: The Trader’s Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About CÜR Media
CÜR Media is creating a next generation social music experience through the planned launch of CÜR Music, a social streaming music application and website that is being designed to enable its users to go beyond the limitations of traditional music streaming services. CÜR Music will unlock the true expressive nature of an individual’s connection with their music by fostering personalization, sharing and creativity. With CÜR Music it’s not just about streaming, it’s about what the music means to you and how you want to express that to the world. For more information please visit www.curmusic.com.

About CEO Tom Brophy
Mr. Brophy has been involved in Executive roles of start-ups and growth companies since 1994. Mr. Brophy was the CFO of Interactive Search Holdings, the first company to mass distribute search toolbars across the web, pioneering the search toolbar business which became a multi-billion dollar industry. The Company was also the first company to mass distribute smiley emoticons as part of its toolbar distribution strategy. Mr. Brophy started his career at Deloitte & Touche, has been the Chief Financial Officer of several startup and growth companies and has several successful exits. He has also been the Chief Financial Officer of a public company.

About The Traders Network Show
For the past six years “The Traders Network Show” has been hosted and broadcasted live daily on Clear Channel DFW 1190AM KFXR from 7am – 8am, Monday-Friday and Saturdays from 1pm – 3pm ET. Host Michael Yorba interviews the front-page titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and investment insights in a new light and keeps audiences asking for more. Shift your thinking and join us as we deliver “tomorrow’s ideas today” on iHeart Radio and Clear Channel’s The Traders Network Show.

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the development of a commercially viable streaming music product, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the Company’s ability to negotiate economically feasible agreements with the major and independent music labels and publisher rights organizations, and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii), (iv) and (v) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the length of time associated with development of mobile applications and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies.

A 1800PublicRelations.com PR Event.

CONTACT INFORMATION

Interview Press / Media Contact:
Matthew Bird
President
1-800-PublicRelations, Inc.
917.409.8211
matt.bird@1800pr.com
www.1800pr.com

Investor Contact:
Ascendant Partners, LLC
Fred Sommer
+(732)410-9810
fred@ascendantpartnersllc.com

By support Traders Network Show Comments Off Read more...

16 Feb

CEO Dr. Robin Smith of NeoStem to Discuss Agreement to Acquire California Stem Cell, Inc. Live Today on Clear Channel’s “The Traders Network Show”

Interview Airs at 2:30pm EDT / 1:30pm CDT / 11:30am PDT on the Traders Network Radio Show, Hosted by Michael Yorba

NEW YORK, NY–(Apr 15, 2014) – NeoStem, Inc. (NASDAQ: NBS) (“NeoStem”), a leader in the emerging cellular therapy industry, announced today that Chairman and CEO, Dr. Robin Smith, will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio’s The Traders Network Show. In this exclusive 2-segement interview, Dr. Smith will go over the strategic details of their contract to acquire California Stem Cell, Inc. (CSC) .

We encourage shareholders, analysts, industry professional and all interested parties to tune in and listen live via Clear Channel’s nationally syndicated iHeart Radio stream.

Date: Tue, April 15, 2014
Start Time: 11:30am PDT | 1:30pm CDT | 2:30pm EDT (U.S.)
Network: Clear Channel
Station: DFW 1190AM KFXR
Show: The Traders Network
Host: Michael Yorba
Live iHeart Radio Stream: http://www.iheart.com/live/4276/?autoplay=true

About Michael Yorba
Mr. Yorba is the founder of Yorba Media and featured host on Clear Channel. For the past six years he has produced and hosted The Traders Network Show broadcasted live daily on Clear Channel DFW 1190AM KFXR from 1pm – 3pm CT, Monday-Friday.

Michael Yorba interviews the front-page Titans about the latest in capital markets, CEO milestones, trading tools, real estate acquisitions and market trends. Learn how the experts use risk management techniques to build fully diversified portfolios and what it takes to put up big board earnings. It’s a fast moving, high-energy show that presents stocks, commodities, bonds, forex, derivatives, real estate, political trends, technology trends, crowd funding and impact investment insights in a new light and keeps audience asking for more… shift your thinking and join us as we deliver “tomorrow’s ideas today” on Clear Channel’s The Traders Network Show.

About NeoStem, Inc.
NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s ability to consummate the CSC acquisition and the Company’s ability to develop and grow its business, the successful development of cellular therapies, including with respect to the Company’s research and development and clinical evaluation efforts in connection with the Company’s CD34 Cell Program and T Regulatory Cell Program and other cell therapies (including Melapuldencel-T if CSC is successfully acquired), the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company’s contract development and manufacturing business. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2014 and in the Company’s periodic filings with the SEC. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

A www.1800PublicRelations.com PR Event

Contact
Investor
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: +1-646-597-6979
Email: mrice@lifesciadvisors.com

Media
NeoStem, Inc.
Eric Powers
Manager of Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@neostem.com

Press/Media
Matthew Bird, President
MUNCmedia Public Relations
+1 (917) 409-8211
matt.bird@muncmedia.com
www.muncmedia.com

By support Traders Network Show Comments Off Read more...